lol...if you look at the incidence rate of cml multiplied by the incidence of failures of treatment due to the t315i mutation ( there are about 20 different muts out there) you don't really get that many patients to treat....still beats me how this can be wildly profitable....
undervalued biotech, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)